bexopro
    • Advanced Search
  • Guest
    • Login
    • Register
    • Night mode
Thomas Schmitt Cover Image
User Image
Drag to reposition cover
Thomas Schmitt Profile Picture
Thomas Schmitt

@thomasm

  • Timeline
  • Groups
  • Likes
  • Following
  • Followers
  • Photos
  • Videos
  • Reels
Thomas Schmitt profile picture Thomas Schmitt profile picture
Thomas Schmitt
2 d

https://www.creative-diagnosti....cs.com/high-risk-hpv

High-Risk HPV L1 Virus-Like Particles Produced in Yeast for Research and Assay Development

HPV is a non-enveloped, double-stranded DNA virus with a T = 7 icosahedral capsid composed of 72 L1 pentamers (capsomeres), which are paired with L2 monomers. The L1 and L2 proteins have similar molecular weights (approximately 55kDa), with minor differences among different HPV genotypes. HPV has evolved a highly refined infection mechanism and exhibits specificity regarding the species, tissues and cell types it infects. Furthermore, the HPV virion enters the host via routes other than body fluids, resulting in a weak immune response from the host against neutralizing epitopes on the capsid. Given this low immune pressure, as well as the fact that the human antiviral immune response is primarily driven by type-specific neutralization, the HPV phylogeny is highly complex, with more than 200 distinct genotypes having accumulated to date. As there is currently no efficient method of extracting natural antigens from cultures, serological testing for HPV relies primarily on the use of “virus-like particles” (VLPs). When expressed via recombinant technology, the major HPV capsid protein L1 self-assembles into VLPs. These VLPs do not contain the viral genome, but they present type-specific conformational epitopes that are similar to those found in real viral particles. HPV L1 VLPs can induce high-titre, type-specific neutralizing antibodies and form the basis of current preventive vaccines. To better support scientific research in HPV immunology and diagnostics, Creative Diagnostics now provides researchers with high-risk HPV L1 VLPs produced in yeast, which are ideal for HPV-related research, diagnostic reagent development, antibody evaluation and viral antigen characterization. These antigens are based on the major capsid protein L1 of clinically significant high-risk HPV types. When properly expressed and processed, the L1 protein self-assembles into VLPs that resemble natural HPV capsids in structure but do not contain viral genomic material. This makes L1 VLPs non-infectious antigenic reagents that are particularly suitable for research that require the presentation of a natural capsid structure. Creative Diagnostics’ new product portfolio covers nine high-risk genotypes relevant to cervical cancer research, HPV epidemiology, and immune response profiling, including HPV16, HPV18, HPV31, HPV33, HPV35, HPV45, HPV52, HPV59 and HPV68. This comprehensive testing panel enables the parallel comparison of subtype-specific antibody responses, cross-reactivity and antigenic performance across multiple high-risk genotypes. For researchers and assay developers who are interested in evaluating the High-Risk HPV L1 VLPs portfolio, product specifications, availability, application-specific requirements , or requesting bulk production, please visit https://www.creative-diagnostics.com/high-risk-hpv-l1-vlps-produced-in-yeast.htm
Like
Comment
Share
Thomas Schmitt profile picture Thomas Schmitt profile picture
Thomas Schmitt
9 w

https://qbd.creative-diagnosti....cs.com/untargeted-me

Untargeted Metabolomics Services - Creative Diagnostics

Metabolomics has become a key tool for understanding the effects of external or pathological stressors on biological systems. Over the past decade, both targeted and untargeted metabolomics have demonstrated tremendous potential. They enable the analysis of phenotypic changes in metabolites, and provide comprehensive information on the outcomes of normal physiological functions and the effects of various pathophysiological stimuli in tissues, cells, and bodily fluids. In the context of drug discovery, systems biology aims to combine ''omics'' approaches with bioinformatics methods to enhance the success rate of drug candidate screening and the identification of clinical indications. Untargeted metabolomics is a ‘hypothesis-generating discovery strategy’ that identifies metabolites and detects disturbances (including early signs of disease) by comparing sample groups (e.g. case versus control groups). Targeted metabolomics helps to gather critical information in the life sciences and reveals new strategies for treating major clinical diseases such as cancer, cardiovascular disease, diabetes and drug toxicity. Due to its importance in biomarker discovery, research is currently focused on enhancing the translational potential of non-targeted metabolomics. Both approaches have their own advantages and disadvantages, and they are usually employed together to identify differentially expressed metabolites and accurately determine their masses. This enables in-depth research and analysis of metabolic biomarkers. Targeted and non-targeted metabolomics are widely used in the identification of foods, research into diseases, the validation of animal models, the discovery of biomarkers, the diagnosis of diseases, the development of drugs, the screening of drugs, the evaluation of drugs, and clinical research into plant and microbial metabolism. Creative Diagnostics now offers untargeted metabolomics services based on high-resolution LC-MS/MS technology, supporting research projects in the pharmaceutical and biotechnology industries, academia, and translational research. Through the integration of optimized sample preparation, high-resolution mass spectrometry, advanced bioinformatics and biological interpretation, Creative Diagnostics has developed a thorough workflow that allows researchers to identify metabolic changes related to disease progression, drug responses and cellular functions. The platform supports a wide range of applications, including global metabolite profiling, differential metabolite analysis, biomarker discovery, mechanism of action studies, drug efficacy assessment, host-pathogen interaction studies, immunometabolism research and multi-omics integration. Combining high-sensitivity LC-MS/MS data acquisition with robust statistical analysis, Creative Diagnostics’ untargeted metabolomics services reveal metabolic pathway-level changes that are difficult to detect using targeted analysis methods alone. Additionally, Creative Diagnostics implements rigorous quality control (QC) procedures throughout the analytical workflow to ensure consistent and reproducible data. These QC strategies include using pooled QC samples, monitoring system suitability to track instrument performance, normalizing with internal standards, and correcting for batch effects. To learn more about Creative Diagnostics'' Untargeted Metabolomics Services, please visit: https://qbd.creative-diagnostics.com/untargeted-metabolomics-services.html. About Creative Diagnostics Creative Diagnostics is a global leader in the development and manufacturing of innovative tools and reagents for bioprocess impurity analysis. The company offers a comprehensive portfolio of solutions to support researchers in the quality control of biologics and provides biopharmaceutical quality, purity and safety assays, analytical methods and applications for the biotechnology and biopharmaceutical industries.
Like
Comment
Share
Thomas Schmitt profile picture Thomas Schmitt profile picture
Thomas Schmitt
10 w

https://www.creative-diagnosti....cs.com/bundibugyo-vi

Reagent Solutions to Support Outbreak Response Against Bundibugyo Virus

Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has expanded its research support suite and announced a comprehensive range of products and services targeted at the Bundibugyo Virus (BDBV). These offerings aim to accelerate viral detection, characterization, and countermeasure development, thereby advancing vaccine candidate evaluation, antiviral discovery, and diagnostic assay development. Ebola haemorrhagic fever is a syndrome that can lead to death within a few days of the onset of symptoms. It directly affects the immune system and the vascular bed, resulting in an extremely high mortality rate. The Ebola virus (EBOV) belongs to the Filoviridae family within the order Mononegavirales. The Filoviridae family comprises three genera: Ebola virus, Marburg virus and Cueva virus. The Ebola virus genus is further subdivided into five species, each represented by a unique virus: Taï Forest Ebola virus (TAFV), Reston Ebola virus (RESTV), Sudan Ebola virus (SUDV), Bundibugyo Ebola virus (BDBV), and Zaire Ebola virus (EBOV). EBOV is the most prominent of these. BDBV is considered a less virulent Ebola virus due to its lower case fatality rate in human and animal outbreaks (25% to 51%). In contrast, the case fatality rate following Ebola virus infection in non-human primates is almost always fatal. While in-depth transcriptomic analyses have been conducted on samples from human patients and non-human primates infected with the Ebola virus, no such studies have been conducted on the Bundibugyo virus. The clinical manifestations of Ebola virus infection in humans and non-human primates (NHPs) are similar and include viremia, cytokine storm and consumptive coagulopathy, which can lead to septic shock and multiple organ failure. The virus initially replicates in monocytes and dendritic cells before spreading to hepatocytes, endothelial cells and epithelial cells. In May 2026, the World Health Organization (WHO) received a report of a highly fatal Bondibougio virus outbreak in Mongbwalu Health Zone, Ituri Province, Democratic Republic of the Congo (DRC), which resulted in deaths among healthcare workers. The Bondibougio virus forms filamentous viral particles and is closely related to the Zaire Ebola virus. It is one of several viruses that can cause Ebola in humans, presenting as viral haemorrhagic fever. Unlike Ebola virus disease, there are currently no approved vaccines or specific treatments for the Bondibougio virus, but early supportive care can save lives. This outbreak has once again drawn global attention to Ebola, highlighting the urgent need to develop effective diagnostic and preventive products. Recognizing the urgent need for more effective tools to combat BDBV, Creative Diagnostics is monitoring the current outbreak closely and has swiftly introduced a range of products to support BDBV infection and vaccine research, including antibodies, ELISA kits, RT-PCR kits, and nucleic acid standard references. Creative Diagnostics will continue to provide research solutions to assist scientists, public health researchers and biotechnology organizations in deeper understanding of this emerging pathogen. To learn more about Creative Diagnostics'' research products and outbreak response reagents, please visit https://www.creative-diagnostics.com/bundibugyo-virus-bdbv-outbreak-response.htm. About Creative Diagnostics Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components, and critical assay reagents. In addition to providing contract R&D and biologic manufacturing services for diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market, the company aims to continue to act as a trusted source for all researchers'' assay development and manufacturing needs.
Like
Comment
Share
Thomas Schmitt profile picture Thomas Schmitt profile picture
Thomas Schmitt created a new article
17 w

Respiratory Syncytial Virus Animal Model Services for Antiviral and Vaccine Discovery | #respiratory Syncytial Virus Animal Model

Respiratory Syncytial Virus Animal Model Services for Antiviral and Vaccine Discovery

Respiratory Syncytial Virus Animal Model Services for Antiviral and Vaccine Discovery

Respiratory Syncytial Virus Animal Model Services for Antiviral and Vaccine Discovery
Like
Comment
Share
Thomas Schmitt profile picture Thomas Schmitt profile picture
Thomas Schmitt created a new article
17 w

Tritosome Reagents to Advance In Vitro Characterization of ADCs and Oligonucleotide Therapeutics | #tritosome Reagents

Tritosome Reagents to Advance In Vitro Characterization of ADCs and Oligonucleotide Therapeutics

Tritosome Reagents to Advance In Vitro Characterization of ADCs and Oligonucleotide Therapeutics

Tritosome Reagents to Advance In Vitro Characterization of ADCs and Oligonucleotide Therapeutics
Like
Comment
Share
 Load more posts
    Info
    • Male
    • posts 7
  • 12/14/00
  • Living in United States
    Albums 
    (0)
    Following 
    (20)
    Followers 
    (21)
    Likes 
    (0)
    Groups 
    (0)

© 2026 BexoPRO - Your Social Networking Hub

Language

  • About
  • Directory
  • Blog
  • Contact Us
  • More
    • Privacy Policy
    • Terms of Use
    • Request a Refund

Unfriend

Are you sure you want to unfriend?

Report this User

Important!

Are you sure that you want to remove this member from your family?

You have poked Thomasm

New member was successfully added to your family list!

Crop your avatar

avatar

© 2026 BexoPRO - Your Social Networking Hub

  • Home
  • About
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • Request a Refund
  • Blog
  • Language

© 2026 BexoPRO - Your Social Networking Hub

  • Home
  • About
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • Request a Refund
  • Blog
  • Language

Comment reported successfully.

Post was successfully added to your timeline!

You have reached your limit of 5000 friends!

File size error: The file exceeds allowed the limit (92 MB) and can not be uploaded.

Your video is being processed, We’ll let you know when it's ready to view.

Unable to upload a file: This file type is not supported.

We have detected some adult content on the image you uploaded, therefore we have declined your upload process.

Share post on a group

Share to a page

Share to user

Your post was submitted, we will review your content soon.

To upload images, videos, and audio files, you have to upgrade to pro member. Upgrade To Pro

Edit Offer

0%

Add tier








Select an image
Delete your tier
Are you sure you want to delete this tier?

Reviews

In order to sell your content and posts, start by creating a few packages. Monetization

Pay By Wallet

Add Package

Delete your address

Are you sure you want to delete this address?

Remove your monetization package

Are you sure you want to delete this package?

Unsubscribe

Are you sure you want to unsubscribe from this user? Keep in mind that you won't be able to view any of their monetized content.

Payment Alert

You are about to purchase the items, do you want to proceed?
Request a Refund

Language

  • Arabic
  • Bengali
  • Chinese
  • Croatian
  • Danish
  • Dutch
  • English
  • Filipino
  • French
  • German
  • Hebrew
  • Hindi
  • Indonesian
  • Italian
  • Japanese
  • Korean
  • Persian
  • Portuguese
  • Russian
  • Spanish
  • Swedish
  • Turkish
  • Urdu
  • Vietnamese